Sarah DeVos, PhD

Director and Principal Scientist at Denali Therapeutics

Speaker

Dr. Sarah DeVos, Ph.D, is currently a Director and Principal Scientist at Denali Therapeutics Inc focusing on neurodegenerative disease drug discovery and development. She co-leads the Preclinical Translational Sciences function and manages preclinical model development and biomarker in vivo assessments across Denali’s large molecule portfolio. Additionally, Dr. DeVos is the Platform Lead for the oligonucleotide transport vehicle (OTV) programs at Denali. In this role, she liaises with multiple cross-functional teams, including protein and chemical engineering, pharmacology sciences, biomarker sciences, and safety sciences. She also serves on the joint scientific committee collaboration with Secarna Pharmaceuticals for ASO bioinformatics and lead identification.

Over the course of her career, Dr. DeVos has worked closely with peers in both academia and industry to better understand the druggability of neurodgenerative disorders, primarily focusing on Alzheimer’s Disease (AD) and Frontotemporal Dementia (FTD). She has published numerous papers and patents in the neurodgenerative and oligonucleotide space, with dedicated passion towards merging these two areas.

Prior to starting her career in industry at Denali Therapeutics, Dr. DeVos received her Ph.D. in Neuroscience from Washington University in St Louis as a member in Dr. Timothy Miller’s Lab and her B.S. degree in Neuroscience from Central Michigan University. After receiving her Ph.D, she went on to perform her postdoctoral research in the Department of Neurology at Massachusetts General Hospital in Dr. Bradley Hyman’s Lab.